All News

At NCCN 2026, Anjali Albanese discussed how young adults with cancer face grief, isolation and loss of control that impact their emotional well-being.

Gotistobart improved responses and survival versus docetaxel in pretreated squamous NSCLC, offering a potential chemo-free option with durable benefit in some patients.

Dr. Michael K. Wong explains why immunotherapy makes skin hypersensitive, and how to spot red-flag reactions during melanoma care.

Learn about breast angiosarcoma, a rare blood vessel cancer. Discover the signs of primary and secondary cases to help guide your oncology discussion.

Dr. Charles Peyton discusses the growing number of bladder cancer therapies and emphasizes the importance of personalized care and patient education.

Dr. Thomas Flaig highlights the importance of multidisciplinary care and clinical trials in guiding personalized bladder cancer treatment decisions.

Dr. Michael Wong shares "sun smart" tips for melanoma survivors, debunking tanning myths and highlighting why clothing is better than sunscreen alone.

Moving into a new home often means sorting through years of belongings. Sometimes, hidden in a box, we uncover pieces of the past that force us to confront what we’ve endured.

The latest episode of the "Breast Cancer Briefing" podcast highlights the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

The NexTGen team launches the world's largest CAR-T cell trial for pediatric solid tumors, offering new hope for children with relapsed cancer.

Darlifarnib plus Cabometyx showed tumor responses in resistant kidney cancer following prior treatment.

An expert discusses the need to tailor treatment duration in bladder cancer, balancing improved outcomes with toxicity and exploring new tools.

Tamera Anderson-Hanna reflects on survivorship, redefining life with family, travel, purpose and giving back while embracing time as a precious guide.

Patients with cancer have a new generic option for methotrexate injection following FDA approval of a therapeutic equivalent for multiple conditions.

The FDA accepted an investigational new drug application for chemo-related neuropathy, advancing a potential non-opioid treatment into a clinical trial.

The OPTIMAL trial finds oral DHP107 is as effective as IV paclitaxel for patients with advanced breast cancer while reducing side effects like neuropathy.

Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase 2 trial.

A 30-year study reveals one in six AYA cancer survivors develop a new primary neoplasm, with risks highest for breast and oral cancer survivors.

Before my daughter was diagnosed with breast cancer, the “M” word was not a part of my vocabulary.

PDS01ADC showed high response rates in metastatic colorectal cancer in a phase 2 trial after prior treatment.

After an aggressive breast cancer diagnosis, psychologist Loraine Alderman retires to bridge gaps in patient literature through powerful advocacy.

Dr. Sandy Srinivas explains how age, comorbidities and medications influence personalized prostate cancer treatment decisions.

Dr. W. Fraser Symmans explains how ctDNA is replacing CTCs to monitor breast cancer, detect mutations and track minimal residual disease

Meet Dr. Susan MacDonald, a urologist with stage 4 breast cancer who is the host of CURE's new vlog series, "Demystifying the Darkness."

Emactuzumab improved tumor response and function in TGCT, showing rapid, durable benefits in a phase 3 trial with a short-course treatment approach.

Dr. Costas Bizekis discusses how minimally invasive surgery is improving recovery, reducing complications and enhancing outcomes in esophageal cancer.

Stage 1 urothelial carcinoma is highly treatable; learn about diagnosis, treatment options and how to reduce recurrence risk through ongoing monitoring.

Meetings like SGO drive collaboration and patient-centered progress, as Dr. Ginger J. Gardner highlights their role in advancing access and research.